CALGB 50803 (Alliance): A phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma.Peter Martin, Bruce D. Cheson, Sin‐Ho Jung et al.|Journal of Clinical Oncology|2014Cited by 40
Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa).Lisa A. Carey, Clifford A. Hudis, Maggie C.U. Cheang et al.|Journal of Clinical Oncology|2014Cited by 24